Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Recruiting Phase 2 Interventional

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

NCT05733598
View directory record Official record
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions
RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02809053
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
SAIT101, MabThera®
Biological
Lead sponsor
Archigen Biotech Limited
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 4:07 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

NCT00515398
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II
Interventions
Observation
Other
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 30, 2026, 4:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Characterization of Movement Disorders and Dementias

NCT02014246
View directory record Official record
Conditions
Dementia, Movement Disorder
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2059
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Recruiting Phase 2 Interventional

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
LN-145
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
27
States / cities
Gilbert, Arizona • Miami, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

Ethanol Locks for the Treatment of Central Venous Line Infections

NCT00680459
View directory record Official record
Conditions
Bloodstream Infection
Interventions
70% ethanol, heparin flush solution
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
6 Months to 23 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

Antifungal Locks to Treat Fungal-related Central Line Infections

NCT00936910
View directory record Official record
Conditions
Central Line Fungal Infections
Interventions
amphotericin B liposomal (Ambisome)
Drug
Lead sponsor
Bill McGhee
Other
Eligibility
30 Days to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 30, 2026, 4:07 PM EDT
Completed No phase listed Observational

SAFETY: Stabilization Points to Third Hospital Line Assessment oF the Impact of the usE of Infrascanner Model 2500 to Provide Decision Support for Diagnosis/Screening of Traumatic Brain InjurY in Ukraine

NCT07014748
View directory record Official record
Conditions
Traumatic Brain Hemorrhage
Interventions
Handheld brain hematoma detector
Diagnostic Test
Lead sponsor
InfraScan, Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Terminated Phase 1 Interventional

Vascular Sealant Study

NCT00618358
View directory record Official record
Conditions
Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions
Vascular Sealant System, Gelfoam/Thrombin
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

NCT00752050
View directory record Official record
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 30, 2026, 4:07 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

NCT01472965
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection
Interventions
ethanol, heparin-saline placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 30, 2026, 4:07 PM EDT
Active, not recruiting Phase 1 Interventional

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

NCT05306457
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNS10-NPC-GDNF
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 4:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

NCT06788756
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML)
Interventions
Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Drug
Lead sponsor
Moleculin Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Not applicable Interventional Results available

Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients

NCT01967836
View directory record Official record
Conditions
Cancer-related Problem/Condition, Ambulatory Care
Interventions
Glad Press 'n Seal
Device
Lead sponsor
Maureen T Greene
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Milwaukee, Wisconsin • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 30, 2026, 4:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Central Line Placement-EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION

NCT02602665
View directory record Official record
Conditions
Vascular Access Complication
Interventions
Shallow catheter tip placement, Deep catheter tip placement
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT00876395
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Placebo, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
25
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 30, 2026, 4:07 PM EDT
Recruiting Phase 4 Interventional

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
(taurolidine and heparin) catheter lock solution, Standard of Care
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT04475939
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Niraparib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

NCT00089999
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 30, 2026, 4:07 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

NCT06164275
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography, Multigated Acquisition Scan, Pembrolizumab, Positron Emission Tomography, Vinblastine
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Geneva, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 4:07 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Stem Cells in NF1 Patients With Tumors of the Central Nervous System

NCT03332030
View directory record Official record
Conditions
Neurofibromatosis Type 1, Tumors of the Central Nervous System
Interventions
Collection of Stem Cells
Diagnostic Test
Lead sponsor
Roger Packer
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 30, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parental Feelings About Their Child Needing a Central Line

NCT05842356
View directory record Official record
Conditions
Critical Illness, Children, Only, Stress
Interventions
Communication Technique 2
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 30, 2026, 4:07 PM EDT